An Update in Systemic Lupus Erythematosus: Analyzing Optimal Treatment and Management Strategies

Target Audience:

This CME initiative is designed to meet the educational needs of rheumatologists, primary care physicians and other healthcare providers involved in the treatment of patients with systemic lupus.

Program Overview:

This case-based activity will cover the diagnosis and management of patients with Systemic Lupus Erythematosus.

Disclosure Of Unlabeled Use:

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, Drs. Petri and Wallace may mention the use of medications for both FDA-approved and non-approved indications

Method Of Participation:

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information an faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete the post-test and activity evaluation
  4. Physicians who successfully complete the post-test and evaluation will receive CME credit.
  5. All non-physician participants who successfully complete the post-test and evaluation will receive a certificate of participation.
  6. All nurses will receive a CNE certificate.
You will receive your certificate via email.


Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at:

Course Viewing Requirements:

PC: HTML 5 compliant web browser (e.g. latest version of Internet Explorer, Firefox, or Chrome)

MAC: Safari

RELEASE DATE: March 31, 2014
EXPIRATION DATE: March 31, 2015

MEDIUM: Internet

Estimated Time to Complete This Educational Activity: 60 minutes  


Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:

Med Learning Group designates this enduring web activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Listing:

Michelle Petri, MD, MPH
Professor, Department of Medicine
Johns Hopkins University School of Medicine
Director, The Johns Hopkins Lupus Center
Baltimore, Maryland

Daniel J. Wallace, MD
Clinical Professor of Medicine
David Geffen School of Medicine
University of California Los Angeles
Attending Physician
Cedars Sinai Medical Center
Los Angeles, California

Course Reviewer
M. Susan Burke, MD, FACP
Clinical Assistant Professor, Internal Medicine
Thomas Jefferson University Medical School
Senior Advisor, Internal Medicine Clinical Care Center
Lankenau Hospital
Wynnewood, Pennsylvania

CCM/UMA Lead Nurse Planner
Margaret Governo, EdD, APRN BC
Associate Professor
Wagner College
Staten Island, New York


  • Review the new SLICC criteria and the evidence supporting clinical and serological parameters relative importance in the classification of patients with SLE
  • Discuss the benefits and limitations of current agents for SLE, particularly more recent evidence regarding the use of belimumab, corticosteroids, and hydroxychloroquine
  • Evaluate clinical trial evidence for the potential safety, tolerability, and efficacy of new and novel agents in drug development for SLE
  • Discuss risk factors for comorbidities associated with SLE, particularly for cardiovascular disease and comorbid diseases triggered by corticosteroid use
  • Outline the considerations for individualized treatment, strategies for setting treatment goals, and, predictive factors for nonadherence

Financial Disclosure:

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

Course Chair - - Dr. Petri has been involved in clinical trials with GSK, Medimmune, Pfizer, Anthera, and UCB.  She is a consultant with UCB, Lilly, and Merck Serono.

Course Chair - - Dr. Wallace has received consulting fees and has served on the speakers bureau for Abbvie, Amgen, EMD Serono, GlaxoSmithKline, Lilly, Merck, UCB and Pfizer.

MLG Course Reviewer - Dr. Burke receives Consulting Fees from Iroko and Merck & Co., Inc.

CCM/UMA Lead Nurse Planner - - Margaret Governo, EdD, APRN BC has disclosed no significant financial relationships.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:

Matthew Frese, General Manager of Med Learning Group has nothing to disclose.

Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.

Lauren Welch, VP of Accreditation and Outcomes for Med Learning Group has nothing to disclose.

Flavia Piazza, VP, Medical and Scientific Services for Med Learning Group has nothing to disclose.

Lisa Dorin, Program Manager for Med Learning Group has nothing to disclose.